Wen-Tao Yang - Search Results

Year	Number of Results
2003	1
2004	3
2005	8
2006	4
2007	3
2008	10
2009	8
2010	11
2011	10
2012	15
2013	11
2014	7
2015	12
2016	15
2017	15
2018	13
2019	10
2020	18
2021	18
2022	12
2023	13
2024	10

1

Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria.

Xie XQ, Yang Y, Wang Q, Liu HF, Fang XY, Li CL, Jiang YZ, Wang S, Zhao HY, Miao JY, Ding SS, Liu XD, Yao XH, Yang WT, Jiang J, Shao ZM, Jin G, Bian XW. Xie XQ, et al. Among authors: yang wt. Cell Res. 2023 Mar;33(3):215-228. doi: 10.1038/s41422-022-00766-z. Epub 2023 Jan 10. Cell Res. 2023. PMID: 36627348 Free PMC article.

2

Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.

Zhao S, Ma D, Xiao Y, Li XM, Ma JL, Zhang H, Xu XL, Lv H, Jiang WH, Yang WT, Jiang YZ, Zhang QY, Shao ZM. Zhao S, et al. Among authors: yang wt. Oncologist. 2020 Oct;25(10):e1481-e1491. doi: 10.1634/theoncologist.2019-0982. Epub 2020 Jun 1. Oncologist. 2020. PMID: 32406563 Free PMC article.

3

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.

Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, Song XQ, Hu X, Yang WT, Chai WJ, Guo XM, Chen XZ, Xu YH, Zhu XY, Zou JJ, Wang ZH, Jiang YZ, Shao ZM. Wu SY, et al. Among authors: yang wt. Mol Cancer. 2022 Mar 25;21(1):84. doi: 10.1186/s12943-022-01536-6. Mol Cancer. 2022. PMID: 35337339 Free PMC article. Clinical Trial.

4

Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer.

Zhao S, Chen DP, Fu T, Yang JC, Ma D, Zhu XZ, Wang XX, Jiao YP, Jin X, Xiao Y, Xiao WX, Zhang HY, Lv H, Madabhushi A, Yang WT, Jiang YZ, Xu J, Shao ZM. Zhao S, et al. Among authors: yang wt. Nat Commun. 2023 Oct 25;14(1):6796. doi: 10.1038/s41467-023-42504-y. Nat Commun. 2023. PMID: 37880211 Free PMC article.

5

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.

Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Among authors: yang wt. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.

6

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.

Dai LJ, Ma D, Xu YZ, Li M, Li YW, Xiao Y, Jin X, Wu SY, Zhao YX, Wang H, Yang WT, Jiang YZ, Shao ZM. Dai LJ, et al. Among authors: yang wt. Nat Commun. 2023 Aug 22;14(1):5112. doi: 10.1038/s41467-023-40715-x. Nat Commun. 2023. PMID: 37607916 Free PMC article.

7

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.

Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, Zhou YF, Fu T, Lin CJ, Dai LJ, Liu CL, Zhao S, Su GH, Hou W, Liu Y, Chen Q, Yang J, Zhang N, Zhang WJ, Liu W, Ge W, Yang WT, You C, Gu Y, Kaklamani V, Bertucci F, Verschraegen C, Daemen A, Shah NM, Wang T, Guo T, Shi L, Perou CM, Zheng Y, Huang W, Shao ZM. Jiang YZ, et al. Among authors: yang wt. Nat Cancer. 2024 Apr;5(4):673-690. doi: 10.1038/s43018-024-00725-0. Epub 2024 Feb 12. Nat Cancer. 2024. PMID: 38347143

8

Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.

Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. Fan L, et al. Among authors: yang wt. Lancet Oncol. 2024 Feb;25(2):184-197. doi: 10.1016/S1470-2045(23)00579-X. Epub 2024 Jan 8. Lancet Oncol. 2024. PMID: 38211606 Clinical Trial.

9

Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.

Wang H, Ding XH, Liu CL, Xiao Y, Shui RH, Li YP, Chen C, Yang WT, Liu S, Chen CS, Shao ZM, Jiang YZ. Wang H, et al. Among authors: yang wt. J Natl Cancer Inst. 2023 Dec 6;115(12):1586-1596. doi: 10.1093/jnci/djad154. J Natl Cancer Inst. 2023. PMID: 37549066

10

Unveiling the duality of Pantoea dispersa: A mini review.

Yang WT, Yi YJ, Xia B. Yang WT, et al. Sci Total Environ. 2023 May 15;873:162320. doi: 10.1016/j.scitotenv.2023.162320. Epub 2023 Feb 18. Sci Total Environ. 2023. PMID: 36801414 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

208 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Results by year